A 62-year-old woman with acute myocardial infarction complicated by cardiogenic shock and pulmonary edema is admitted to the ICU. She is hypotensive (SBP 85 mmHg) and requires inotropic support. Which is the drug of choice for improving cardiac output and systemic perfusion in this setting?

Question

Accepted Answer

B. Dobutamine. ## Inotropic Support in Cardiogenic Shock Post-MI

**Key Point:** Dobutamine is the inotrope of choice for acute cardiogenic shock complicating myocardial infarction because it increases myocardial contractility (β₁-adrenergic effect) while reducing systemic vascular resistance (β₂-mediated vasodilation), thereby improving cardiac output without excessive afterload increase.

### Pathophysiology of Cardiogenic Shock

```mermaid
flowchart TD
  A[Acute MI with extensive myocardial necrosis]:::outcome --> B[Reduced left ventricular contractility]:::outcome
  B --> C[Decreased cardiac output]:::outcome
  C --> D[Hypotension & tissue hypoperfusion]:::urgent
  D --> E{Compensatory mechanisms}:::decision
  E -->|Sympathetic activation| F[Increased SVR & HR]:::action
  E -->|Fluid retention| G[Pulmonary edema]:::urgent
  F --> H[Increased myocardial oxygen demand]:::outcome
  H --> I[Worsening ischemia & infarct extension]:::urgent
  J[Inotropic support needed]:::action --> K[Restore cardiac output & perfusion]:::outcome
```

### Catecholamine Receptor Effects & Inotrope Selection

| Agent | α-Effect | β₁-Effect | β₂-Effect | Dopaminergic | Clinical Use in Cardiogenic Shock |
| --- | --- | --- | --- | --- | --- |
| **Dobutamine** | None | +++ | ++ | No | First-line; ↑ contractility, ↓ SVR |
| **Dopamine** | ++ (high dose) | ++ | + | ++ | Second-line; dose-dependent effects |
| **Epinephrine** | +++ | +++ | ++ | No | Refractory shock; ↑ SVR risk |
| **Milrinone** | None | None | None | No | Phosphodiesterase inhibitor; ↓ SVR, ↑ contractility |

### Dobutamine Dosing & Hemodynamic Effects

**Dosing:**
- Initial: 2.5–5 mcg/kg/min IV infusion
- Titrate: up to 10–20 mcg/kg/min based on response
- Onset: 1–2 minutes; peak effect 10 minutes

**Hemodynamic Profile:**
- ↑ Cardiac output (via β₁-mediated inotropy)
- ↓ Systemic vascular resistance (via β₂-mediated vasodilation)
- ↓ Left ventricular filling pressure (reduces pulmonary edema)
- ↑ Heart rate (minor; less than with epinephrine)
- ↑ Myocardial oxygen consumption (modest)

**High-Yield:** Dobutamine improves both systolic function AND reduces afterload, making it ideal for cardiogenic shock with pulmonary edema. Unlike dopamine at high doses, it does not increase SVR excessively.

### Clinical Pearl
In cardiogenic shock post-MI, the goal is to restore coronary perfusion pressure (diastolic BP ≥60 mmHg) while reducing left ventricular filling pressures. Dobutamine achieves both by increasing contractility and reducing SVR, whereas pure vasoconstrictors (α-agonists) worsen the situation by increasing afterload and myocardial oxygen demand.

### Adjunctive Measures
- **Vasodilators** (nitroglycerin, nitroprusside): reduce preload and afterload but may worsen hypotension
- **Mechanical support:** Intra-aortic balloon pump (IABP) or extracorporeal membrane oxygenation (ECMO) for refractory shock
- **Urgent revascularization:** PCI or CABG to salvage viable myocardium

**Warning:** Do NOT use pure beta-blockers (esmolol, metoprolol) or non-dihydropyridine calcium channel blockers (diltiazem) in cardiogenic shock — they worsen contractility and can precipitate cardiovascular collapse.

Answer

A. Diltiazem

Answer

C. Nitroglycerin

Answer

D. Esmolol

A 62-year-old woman with acute myocardial infarction complicated by cardiogenic shock and pulmonary edema is admitted to the ICU. She is hypotensive (SBP 85 mmHg) and requires inotropic support. Which is the drug of choice for improving cardiac output and systemic perfusion in this setting?

Explanation

Inotropic Support in Cardiogenic Shock Post-MI

Pathophysiology of Cardiogenic Shock

Catecholamine Receptor Effects & Inotrope Selection

Dobutamine Dosing & Hemodynamic Effects

Clinical Pearl

Adjunctive Measures

Practice similar questions

Join our NEET PG community

Agent	α-Effect	β₁-Effect	β₂-Effect	Dopaminergic	Clinical Use in Cardiogenic Shock
Dobutamine	None	+++	++	No	First-line; ↑ contractility, ↓ SVR
Dopamine	++ (high dose)	++	+	++	Second-line; dose-dependent effects
Epinephrine	+++	+++	++	No	Refractory shock; ↑ SVR risk
Milrinone	None	None	None	No	Phosphodiesterase inhibitor; ↓ SVR, ↑ contractility